NCT02737748: A trial that was reported late by Transwell Biotech Co., Ltd.
This trial has reported, although it was 363 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02737748 |
|---|---|
| Title | A Phase I/II Study to Evaluate the Safety and Efficacy of TWB-103 in Adult Patients With Split-Thickness Skin Graft Donor Site Wounds (DSW) |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 6, 2017 |
| Completion date | May 7, 2021 |
| Required reporting date | May 7, 2022, midnight |
| Actual reporting date | May 5, 2023 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 363 |